[go: up one dir, main page]

PL3978074T3 - TERLIPRESIN FOR THE TREATMENT OF HEPATO-RENAL SYNDROME TYPE 1 - Google Patents

TERLIPRESIN FOR THE TREATMENT OF HEPATO-RENAL SYNDROME TYPE 1

Info

Publication number
PL3978074T3
PL3978074T3 PL21205752.5T PL21205752T PL3978074T3 PL 3978074 T3 PL3978074 T3 PL 3978074T3 PL 21205752 T PL21205752 T PL 21205752T PL 3978074 T3 PL3978074 T3 PL 3978074T3
Authority
PL
Poland
Prior art keywords
terlipresin
hepato
treatment
syndrome type
renal syndrome
Prior art date
Application number
PL21205752.5T
Other languages
Polish (pl)
Inventor
Khurram Jamil
Stephen Chris Pappas
Jim POTENZIANO
Original Assignee
Mallinckrodt Pharmaceuticals Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Pharmaceuticals Ireland Limited filed Critical Mallinckrodt Pharmaceuticals Ireland Limited
Publication of PL3978074T3 publication Critical patent/PL3978074T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/0205—Simultaneously evaluating both cardiovascular conditions and different types of body conditions, e.g. heart and respiratory condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording for evaluating the cardiovascular system, e.g. pulse, heart rate, blood pressure or blood flow
    • A61B5/024—Measuring pulse rate or heart rate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
    • A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring blood gases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
    • A61M27/002—Implant devices for drainage of body fluids from one part of the body to another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G01N33/4925—Blood measuring blood gas content, e.g. O2, CO2, HCO3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/01—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials specially adapted for biological cells, e.g. blood cells
    • G01N2015/016—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1024—Counting particles by non-optical means

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Surgery (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
PL21205752.5T 2014-10-24 2015-10-22 TERLIPRESIN FOR THE TREATMENT OF HEPATO-RENAL SYNDROME TYPE 1 PL3978074T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462068357P 2014-10-24 2014-10-24
US201562151384P 2015-04-22 2015-04-22

Publications (1)

Publication Number Publication Date
PL3978074T3 true PL3978074T3 (en) 2024-08-12

Family

ID=54478246

Family Applications (2)

Application Number Title Priority Date Filing Date
PL15791430T PL3209317T3 (en) 2014-10-24 2015-10-22 Terlipressin for treating hepatorenal syndrome type 1
PL21205752.5T PL3978074T3 (en) 2014-10-24 2015-10-22 TERLIPRESIN FOR THE TREATMENT OF HEPATO-RENAL SYNDROME TYPE 1

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL15791430T PL3209317T3 (en) 2014-10-24 2015-10-22 Terlipressin for treating hepatorenal syndrome type 1

Country Status (15)

Country Link
US (2) US10335452B2 (en)
EP (3) EP3978074B1 (en)
JP (4) JP6673915B2 (en)
CN (2) CN114028536B (en)
AU (1) AU2015335855A1 (en)
CA (1) CA2965325A1 (en)
DK (2) DK3209317T3 (en)
ES (2) ES2987577T3 (en)
FI (1) FI3978074T3 (en)
HR (1) HRP20220225T1 (en)
HU (1) HUE058066T2 (en)
PL (2) PL3209317T3 (en)
PT (2) PT3209317T (en)
SI (1) SI3209317T1 (en)
WO (1) WO2016065117A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2963659C (en) 2008-09-17 2020-06-23 Chiasma Inc. Use of oral octreotride compositions
PL3209317T3 (en) * 2014-10-24 2022-05-23 Mallinckrodt Pharmaceuticals Ireland Limited Terlipressin for treating hepatorenal syndrome type 1
US20210290725A1 (en) * 2014-10-24 2021-09-23 Mallinckrodt Pharmaceuticals Ireland Limited Method of treating patients with hepatorenal syndrome type 1
US20200046798A1 (en) * 2014-10-24 2020-02-13 Mallinckrodt Hospital Products IP Limited Method of treating patients with hepatorenal syndrome type 1
MA46586A (en) * 2016-10-21 2019-08-28 Chiasma Inc TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE
JP7579811B2 (en) 2019-05-22 2024-11-08 バイオヴァイ インコーポレイテッド Terlipressin formulations
CN110251469B (en) * 2019-07-31 2021-11-09 南京康舟医药科技有限公司 Terlipressin acetate preparation and preparation method thereof
EP4051310A1 (en) * 2019-10-30 2022-09-07 Mallinckrodt Hospital Products IP Unlimited Company Method of treating patients with hepatorenal syndrome type 1 and low mean arterial pressure
WO2023183339A1 (en) * 2022-03-22 2023-09-28 Ocelot Bio, Inc. Selective vasopressin receptor agonist for end-stage liver disease
US20240156895A1 (en) * 2022-10-28 2024-05-16 Mallinckrodt Pharmaceuticals Ireland Limited Compositions for improving kidney function in patients with hepatorenal syndrome

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188443A1 (en) 2000-09-15 2002-03-20 Ferring BV Improved protocol for paracentesis
US7785857B2 (en) * 2006-08-31 2010-08-31 Saint Louis University Protein C variant
GB0617581D0 (en) * 2006-09-07 2006-10-18 Ucl Business Plc Biomarkers for assessing liver function
US20080221551A1 (en) * 2007-03-09 2008-09-11 Flowmedica, Inc. Acute kidney injury treatment systems and methods
WO2009037586A2 (en) 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
MX2011004767A (en) * 2008-11-10 2011-09-06 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure.
HUE036081T2 (en) 2009-03-09 2018-06-28 Bioatla Llc Mirac Proteins
NZ596916A (en) 2009-06-08 2013-09-27 Ucl Business Plc Treatment of portal hypertension and restoration of liver function using l-ornithine phenylacetate
WO2012009545A1 (en) * 2010-07-14 2012-01-19 Cumberland Emerging Technologies, Inc Methods of treating hepatorenal syndrome and hepatic encephalopathy with thromboxane-a2 receptor antagonists
JP2012159356A (en) * 2011-01-31 2012-08-23 Mochida Pharmaceut Co Ltd Combined diagnostic marker for sepsis
CN103254295A (en) * 2013-05-31 2013-08-21 青岛国大生物制药股份有限公司 Preparation method of terlipressin
PL3209317T3 (en) * 2014-10-24 2022-05-23 Mallinckrodt Pharmaceuticals Ireland Limited Terlipressin for treating hepatorenal syndrome type 1
JP2017014206A (en) 2015-06-30 2017-01-19 ナノアンティバイオティクス，インコーポレイテッド Ascites treatment

Also Published As

Publication number Publication date
JP2019199485A (en) 2019-11-21
HRP20220225T1 (en) 2022-04-29
PT3209317T (en) 2022-01-19
FI3978074T3 (en) 2024-05-20
US10335452B2 (en) 2019-07-02
ES2904492T3 (en) 2022-04-05
CN114028536A (en) 2022-02-11
CN107206049A (en) 2017-09-26
ES2987577T3 (en) 2024-11-15
JP2021155433A (en) 2021-10-07
US20160113994A1 (en) 2016-04-28
EP3978074B1 (en) 2024-03-06
JP6989571B2 (en) 2022-01-05
PL3209317T3 (en) 2022-05-23
EP3981420A1 (en) 2022-04-13
EP3978074A1 (en) 2022-04-06
PT3978074T (en) 2024-05-13
US20190328831A1 (en) 2019-10-31
JP7346494B2 (en) 2023-09-19
JP2017534618A (en) 2017-11-24
CN114028536B (en) 2024-07-09
CA2965325A1 (en) 2016-04-28
HUE058066T2 (en) 2022-06-28
JP6673915B2 (en) 2020-03-25
JP2022171795A (en) 2022-11-11
EP3209317B1 (en) 2021-12-08
CN107206049B (en) 2021-12-07
DK3978074T3 (en) 2024-05-13
AU2015335855A1 (en) 2017-05-18
WO2016065117A1 (en) 2016-04-28
EP3209317A1 (en) 2017-08-30
DK3209317T3 (en) 2022-02-07
SI3209317T1 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
IL250016B (en) Antisense oligonucleotides for the treatment of type 2 syndrome
IL247452A0 (en) Compounds for the treatment of complement-mediated disorders
HUE051071T2 (en) Use of cannabidiol for the complex treatment of tuberous sclerosis
HUE058737T2 (en) Procedures for the treatment of infections caused by arenaviridae viruses
PL3265053T3 (en) WAYS OF TREATING THE SKIN
MA50674B1 (en) 1,3-Thiazol-2-yl substituted benzamides
LT3882250T (en) TETRAHYDROPYRANILAMINO-PYROLOPYRIMIDINONE FOR USE IN THE TREATMENT OF DISORDERS CAUSED BY BTK
PL3936130T3 (en) Valbenazine dosage regimen for the treatment of hyperkinetic movement disorders
LT3594238T (en) ANTIBODY COMPOSITIONS FOR THE TREATMENT OF TUMORS
EP3564335A4 (en) SURFACE TREATMENT
HUE055263T2 (en) 11-Substituted 24-hydroxysterols for the treatment of NMDA-related conditions
DK3778595T3 (en) Pancreatitis treatment
PL3978074T3 (en) TERLIPRESIN FOR THE TREATMENT OF HEPATO-RENAL SYNDROME TYPE 1
DK3231444T3 (en) New treatment
HUE050944T2 (en) Treatment procedure using tradipitant
DK3215607T3 (en) PHAG THERAPY
BR112016022976A2 (en) METHODS FOR THE TREATMENT OF HCV
IL256206A (en) mct4 inhibitors to treat the disease
KR20180084876A (en) The plasma-
EP3375108A4 (en) DEWLAN TREATMENT
PL3236960T3 (en) Fluralaner for use in the treatment of demodicosis
DK3393478T3 (en) combination therapy
LT3113778T (en) PIRIDASIN DERIVATIVES FOR THE USE OF ANTI-DETECTION PROFILATION OR TREATMENT
EP3362091A4 (en) COMBINATION THERAPY
DK3302478T3 (en) PAC-1 COMBINATION TREATMENT